Last reviewed · How we verify

NCT03300284

Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer

Completed Last updated 21 July 2023
What this trial tests

trial testing Questionnaires in Thyroid Cancer in 186 participants. Completed in 13 July 2023.

Timeline
7 August 2017
Primary endpoint
13 July 2023
13 July 2023

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment186
Start date7 August 2017
Primary completion13 July 2023
Estimated completion13 July 2023
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03300284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing